In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo’s ADC DS-8201 Enters Global PII Study for Colorectal Cancer
March 9, 2018
- Aducanumab Trial Tweak Has No Impact on Probability of Success: Eisai CEO
March 9, 2018
- Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
- Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
- Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
- Insomnia Drug Lemborexant Hits PIII Goals in Sleep Disorders: Eisai
March 8, 2018
- US FDA Approves Latuda for Pediatric Use in Bipolar I Depression: Sumitomo Dainippon
March 8, 2018
- Yoshikazu Aoki Named as New Asahi Kasei Pharma President
March 8, 2018
- Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
- Average NHI Price Reduction Rate of 12.8% for 3 Major Generic Makers: Jiho Tally
March 7, 2018
- Astellas, Tottori Univ. Pair Up to Develop, Commercialize Immunostimulating Gene Loading Oncolytic Virus
March 7, 2018
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Alcon Pharma Reorganizes Marketing System to Boost Market Shares of Major Products including Lucentis
March 5, 2018
- Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
- World’s 1st Commercial Manufacturing Plant for Allogeneic iPSC Therapies Completed: Sumitomo Dainippon
March 2, 2018
- Canaglu Launched in Taiwan: Mitsubishi Tanabe
March 2, 2018
- Galderma Completes Transfer of Japan Rozex Rights to Maruho
March 2, 2018
- Pfizer to Copromote Effexor SR with Sumitomo Dainippon
March 2, 2018
- Daiichi Sankyo US Subsidiary to Restructure Sales Unit with 280 Job Culls, Anticipating Launch of Oncology Agents
March 2, 2018
- Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…